Cone-Beam CT Guided Localization for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new imaging technology called Cone-Beam CT to assist doctors in placing tiny markers in the lungs before surgery. The goal is to facilitate the precise removal of small lung nodules. The trial suits adults with lung nodules planning to undergo a specific type of lung surgery called VATS. Participants should be comfortable with general anesthesia and should not have certain medical devices that the technology could affect. As an unphased trial, this study allows participants to contribute to innovative research that could enhance surgical outcomes for future patients.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this Cone-Beam CT technique is safe for lung cancer localization?
Research has shown that using cone-beam CT (CBCT) to guide marker placement in lung surgery is generally safe. One study found that marking lung nodules with CBCT before surgery was effective and well-tolerated by patients. Another report noted that patients with small lung nodules marked using CBCT experienced few complications. Most patients managed the procedure well, with only minor issues like temporary pain at the site.
The safety of microcoil placement with CBCT has also been studied. Research suggests this method is safe and helps surgeons accurately locate lung nodules during surgery. Overall, both CBCT and microcoil placement have demonstrated promising safety results in previous studies.12345Why are researchers excited about this trial?
Researchers are excited about Cone Beam CT Guided Localization for lung cancer because it offers a more precise method for targeting tumors. Unlike traditional imaging techniques, Cone Beam CT provides a 3D view of the lung, allowing for accurate placement of a microcoil, which can improve the precision of subsequent surgical or therapeutic interventions. This technique aims to enhance the accuracy of tumor localization, potentially leading to better outcomes and fewer complications compared to conventional methods.
What evidence suggests that Cone Beam CT is effective for lung cancer?
Research has shown that using cone-beam CT (CBCT) to guide the placement of tiny markers, called microcoils, for lung cancer surgery is both effective and safe. Studies have found that this method accurately pinpoints small lung nodules with a success rate of 97-98%. This technique precisely marks the nodules, making them easier to remove during surgery. Additionally, it results in fewer complications compared to other methods. Participants in this trial will undergo CBCT-guided microcoil placement, which previous findings suggest is a dependable option for assisting lung surgeries.12456
Are You a Good Fit for This Trial?
Adults over 18 with lung nodules set for microcoil localization before VATS wedge resection can join. Excluded are those who can't consent, tolerate anesthesia, pregnant individuals, patients with RF-sensitive implants, and severely obese patients.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Procedure
Cone-beam CT (Zeego) is used for percutaneous placement and localization of markers for resection of small pulmonary nodules during VATS
Follow-up
Participants are monitored for safety and effectiveness after the procedure
What Are the Treatments Tested in This Trial?
Interventions
- Cone Beam CT localization and placement of microcoil
Cone Beam CT localization and placement of microcoil is already approved in United States, Canada, European Union for the following indications:
- Localization of small pulmonary nodules during VATS
- Localization of small pulmonary nodules during VATS
- Localization of small pulmonary nodules during VATS
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor